Literature DB >> 3028815

Changes in haemodynamics and body fluid volume due to enalapril in patients with essential hypertension on chronic diuretic therapy.

B A van Schaik, G G Geyskes, P Boer, E J Dorhout Mees.   

Abstract

In 12 patients with essential hypertension who remained hypertensive despite chronic chlorthalidone treatment, the effect of 2 weeks of additional therapy with the converting enzyme inhibitor (CEI) enalapril on blood pressure and body fluid volumes has been evaluated. The objective was to examine the influence of a diuretic-stimulated renin-angiotensin-aldosterone system (RAAS) on haemodynamics and body fluid volume. Mean arterial pressure (MAP -21%), total peripheral resistance index (TPRI -22%) and plasma aldosterone concentration (PAC -39%) were decreased, and plasma renin activity (PRA 660%) was increased. The average heart rate (HR), cardiac index (CI), plasma volume (PV), blood volume (BV), extracellular fluid volume (ECFV) and body weight (BW) remained unchanged. A negative correlation was found between the per cent changes in ECFV and PAC. Thus, body fluid volumes during chronic diuretic treatment are well preserved even when the RAAS with its sodium retaining properties is suppressed by CEI. Possible mechanisms are a volume (not angiotensin II) - dependent stimulation of aldosterone and a fall in blood pressure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3028815     DOI: 10.1007/BF00613510

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  Blood and extracellular fluid volume in patients with Bartter's syndrome.

Authors:  P Boer; R J Hené; H A Koomans; M G Nieuwenhuis; G G Geyskes; E J Mees
Journal:  Arch Intern Med       Date:  1983-10

2.  Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats.

Authors:  C Richer; M P Doussau; J F Giudicelli
Journal:  Hypertension       Date:  1983 May-Jun       Impact factor: 10.190

3.  Sodium intake and renal responses to captopril in normal man and in essential hypertension.

Authors:  N K Hollenberg; L G Meggs; G H Williams; J Katz; J D Garnic; D P Harrington
Journal:  Kidney Int       Date:  1981-08       Impact factor: 10.612

4.  Haemodynamic and hormonal changes during acute and chronic diuretic treatment in essential hypertension.

Authors:  J C Roos; P Boer; H A Koomans; G G Geyskes; E J Dorhout Mees
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

5.  Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

Authors:  G P Hodsman; J R Zabludowski; C Zoccali; R Fraser; J J Morton; G D Murray; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

6.  Hemodynamic and antihypertensive effects of the new oral angiotensin-converting-enzyme inhibitor MK-421 (enalapril).

Authors:  F M Fouad; R C Tarazi; E L Bravo; S C Textor
Journal:  Hypertension       Date:  1984 Mar-Apr       Impact factor: 10.190

7.  Effect of dietary sodium on angiotensin-converting enzyme (ACE) inhibition and the acute hypotensive effect of enalapril (MK-421) in essential hypertension.

Authors:  B Jackson; R Cubela; C I Johnston
Journal:  J Hypertens       Date:  1984-08       Impact factor: 4.844

8.  Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects.

Authors:  D M Shoback; G H Williams; S L Swartz; R O Davies; N K Hollenberg
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

9.  Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension.

Authors:  J H Bauer; L B Jones
Journal:  Am J Kidney Dis       Date:  1984-07       Impact factor: 8.860

10.  Reversal of diuretic-induced secondary hyperaldosteronism and hypokalemia by enalapril (MK-421): a new angiotensin-converting enzyme inhibitor.

Authors:  G T Griffing; B H Sindler; S A Aurecchia; J C Melby
Journal:  Metabolism       Date:  1983-07       Impact factor: 8.694

View more
  1 in total

Review 1.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.